211 related articles for article (PubMed ID: 19845417)
1. Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study.
Wild JM; Chiron C; Ahn H; Baulac M; Bursztyn J; Gandolfo E; Goldberg I; Goñi FJ; Mercier F; Nordmann JP; Safran AB; Schiefer U; Perucca E
CNS Drugs; 2009 Nov; 23(11):965-82. PubMed ID: 19845417
[TBL] [Abstract][Full Text] [Related]
2. Vigabatrin and epilepsy: lessons learned.
Wild JM; Ahn HS; Baulac M; Bursztyn J; Chiron C; Gandolfo E; Safran AB; Schiefer U; Perucca E
Epilepsia; 2007 Jul; 48(7):1318-27. PubMed ID: 17635558
[TBL] [Abstract][Full Text] [Related]
3. Modelling the risk of visual field loss arising from long-term exposure to the antiepileptic drug vigabatrin: a cross-sectional approach.
Wild JM; Fone DL; Aljarudi S; Lawthom C; Smith PE; Newcombe RG; Lewis GD
CNS Drugs; 2013 Oct; 27(10):841-9. PubMed ID: 23990316
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review.
Maguire MJ; Hemming K; Wild JM; Hutton JL; Marson AG
Epilepsia; 2010 Dec; 51(12):2423-31. PubMed ID: 21070215
[TBL] [Abstract][Full Text] [Related]
5. Modelling the topography of absolute defects in patients exposed to the anti-epileptic drug vigabatrin and in normal subjects using automated static suprathreshold perimetry of the entire 80° visual field.
Besch D; Schiefer U; Eter N; Burth R; Elger CE; Spitznas M; Dietz K
Graefes Arch Clin Exp Ophthalmol; 2011 Sep; 249(9):1333-43. PubMed ID: 21380539
[TBL] [Abstract][Full Text] [Related]
6. Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer.
Wild JM; Robson CR; Jones AL; Cunliffe IA; Smith PE
Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):917-24. PubMed ID: 16505024
[TBL] [Abstract][Full Text] [Related]
7. Visual fields at school-age in children treated with vigabatrin in infancy.
Gaily E; Jonsson H; Lappi M
Epilepsia; 2009 Feb; 50(2):206-16. PubMed ID: 19215279
[TBL] [Abstract][Full Text] [Related]
8. Vigabatrin-induced peripheral visual field defects in patients with refractory partial epilepsy.
Sergott RC; Bittman RM; Christen EM; Sagar SM
Epilepsy Res; 2010 Dec; 92(2-3):170-6. PubMed ID: 20951555
[TBL] [Abstract][Full Text] [Related]
9. Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity.
Lawthom C; Smith PE; Wild JM
Ophthalmology; 2009 Mar; 116(3):565-71. PubMed ID: 19168223
[TBL] [Abstract][Full Text] [Related]
10. Objective Derivation of the Morphology and Staging of Visual Field Loss Associated with Long-Term Vigabatrin Therapy.
Wild JM; Smith PEM; Knupp C
CNS Drugs; 2019 Aug; 33(8):817-829. PubMed ID: 31250314
[TBL] [Abstract][Full Text] [Related]
11. A lack of clinically apparent vision loss among patients treated with vigabatrin with infantile spasms: The UCLA experience.
Schwarz MD; Li M; Tsao J; Zhou R; Wu YW; Sankar R; Wu JY; Hussain SA
Epilepsy Behav; 2016 Apr; 57(Pt A):29-33. PubMed ID: 26921595
[TBL] [Abstract][Full Text] [Related]
12. Evolution of visual field loss over ten years in individuals taking vigabatrin.
Clayton LM; Stern WM; Newman WD; Sander JW; Acheson J; Sisodiya SM
Epilepsy Res; 2013 Aug; 105(3):262-71. PubMed ID: 23541931
[TBL] [Abstract][Full Text] [Related]
13. Retinal structure and function in vigabatrin-treated adult patients with refractory complex partial seizures.
Sergott RC; Johnson CA; Laxer KD; Wechsler RT; Cherny K; Whittle J; Feng G; Lee D; Isojarvi J
Epilepsia; 2016 Oct; 57(10):1634-1642. PubMed ID: 27580566
[TBL] [Abstract][Full Text] [Related]
14. Patterns of peripapillary retinal nerve fiber layer thinning in vigabatrin-exposed individuals.
Clayton LM; Devile M; Punte T; de Haan GJ; Sander JW; Acheson JF; Sisodiya SM
Ophthalmology; 2012 Oct; 119(10):2152-60. PubMed ID: 22853973
[TBL] [Abstract][Full Text] [Related]
15. The Topographical Relationship between Visual Field Loss and Peripapillary Retinal Nerve Fibre Layer Thinning Arising from Long-Term Exposure to Vigabatrin.
Wild JM; Aljarudi S; Smith PEM; Knupp C
CNS Drugs; 2019 Feb; 33(2):161-173. PubMed ID: 30637668
[TBL] [Abstract][Full Text] [Related]
16. Retinal nerve fibre layer attenuation: clinical indicator for vigabatrin toxicity.
Moseng L; Sæter M; Mørch-Johnsen GH; Hoff JM; Gajda A; Brodtkorb E; Midelfart A
Acta Ophthalmol; 2011 Aug; 89(5):452-8. PubMed ID: 21251242
[TBL] [Abstract][Full Text] [Related]
17. [Vigabatrin and visual field defects. A Danish material with evaluation of different screening methods].
Riise P; Fledelius HC; Rogvi-Hansen Bà
Ugeskr Laeger; 2003 Mar; 165(10):1034-8. PubMed ID: 12645411
[TBL] [Abstract][Full Text] [Related]
18. Vigabatrin-associated loss of vision: rarebit perimetry illuminates the dose-damage relationship.
Frisén L
Acta Ophthalmol Scand; 2004 Feb; 82(1):54-8. PubMed ID: 14738486
[TBL] [Abstract][Full Text] [Related]
19. Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication.
Hardus P; Verduin WM; Postma G; Stilma JS; Berendschot TT; van Veelen CW
Epilepsia; 2000 May; 41(5):581-7. PubMed ID: 10802764
[TBL] [Abstract][Full Text] [Related]
20. Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal.
Newman WD; Tocher K; Acheson JF
Eye (Lond); 2002 Sep; 16(5):567-71. PubMed ID: 12194070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
